Trial Information
A Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine
We are currently recruiting patients.
Inclusion Criteria:
- Fanconi Anemia (confirmed by mitomycin C or DEB chromosomal breakage testing and one
of the following hematological diagnoses: Severe Aplastic Anemia, Myelodysplastic
Syndrome, Acute Myelogenous Leukemia
- Karnofsky or Lansy performance scale > or = to 70%.
- Must have adequate cardiac, hepatic, renal and pulmonary function.
- Must have 7/8 or 8/8 available unrelated donor.
Exclusion Criteria:
- Pregnant or breastfeeding.
- Active CNS leukemic involvement
- Active uncontrolled viral, bacterial or fungal infection
- Positive for HIV.
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
To measure the incidence and quality of engraftment and hematopoietic reconstitution.
Outcome Time Frame:
1, 3, 6 and 12 months post transplant date
Safety Issue:
Yes
Principal Investigator
David A Margolis, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Medical College of Wisconsin
Authority:
United States: Food and Drug Administration
Study ID:
FA 08/89
NCT ID:
NCT01071239
Start Date:
April 2009
Completion Date:
May 2019
Related Keywords:
- Fanconi Anemia
- Fanconi Anemia
- Hematopoietic stem cell transplant
- Anemia
- Fanconi Anemia
- Fanconi Syndrome
Name | Location |
Medical College of Wisconsin |
Milwaukee, Wisconsin 53226 |